CorMedix Inc.
About CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $311.7M
- Net income
- $163.1M
- Total assets
- $826.1M
- Market cap
- $655.9M
- Gross margin
- 88.5%
- Operating margin
- 48.2%
- Net margin
- 52.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $311.7M
- Cost of revenue
- $22.1M
- Gross profit
- $275.7M
- Operating expenses
- $125.6M
- Operating income
- $150.1M
- Income tax
- -$13.0M
- Net income
- $163.1M
- EPS (basic)
- $2.25
- EPS (diluted)
- $2.04
Balance sheet
- Total assets
- $826.1M
- Current assets
- $367.1M
- Total liabilities
- $420.8M
- Current liabilities
- $174.3M
- Shareholders’ equity
- $405.3M
Cash flow
- Operating cash flow
- $175.0M
- Investing cash flow
- -$308.4M
- Financing cash flow
- $238.5M
- Net cash flow
- $105.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $655.9M
- P/E ratio
- 4.2
- EPS (diluted)
- $2.04
- Shares outstanding
- 76.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 13, 2010
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $163.1M in FY2025.
- Revenue grew 163153% from FY2021 to FY2025.
- Gross margin of 88.5%, net margin 52.3%.
- Trading 48% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 4.2.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CorMedix Inc..
Write a review
News about CorMedix Inc.
News & sentiment via Polygon.io
